Evidence map›Paper›PMID 37604841›Full record

ArticleScientific reports2023

Effect of the isotiazole adjuvants in combination with cisplatin in chemotherapy of neuroepithelial tumors: experimental results and modeling.

Vladimir Potkin, Aliaxandr Pushkarchuk, Alexandra Zamaro, Hongwei Zhou, Sergey Kilin, Sergey Petkevich, Irina Kolesnik, Dominik L Michels, Dmitry A Lyakhov, Vladimir A Kulchitsky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Vladimir Potkin *Laboratory of the Chemistry of Heterocyclic Compounds, Institute of Physical Organic Chemistry, National Academy of Sciences of Belarus, 13 Surganov Str., 220072, Minsk, Belarus. potkin@ifoch.bas-net.by.
Aliaxandr Pushkarchuk *Laboratory of the Chemistry of Heterocyclic Compounds, Institute of Physical Organic Chemistry, National Academy of Sciences of Belarus, 13 Surganov Str., 220072, Minsk, Belarus.
Alexandra ZamaroBrain Centre, Institute of Physiology, National Academy of Sciences of Belarus, 28 Akademicheskaya Str., 220072, Minsk, Belarus.
Hongwei ZhouCollege of Biological, Chemical Sciences and Engineering, Jiaxing University, 1 Jiahang Road, Jiaxing, 314001, Zhejiang, China.
Sergey KilinCenter "Quantum Optics and Quantum Informatics", B.I. Stepanov Institute of Physics, National Academy of Sciences of Belarus, 68 Nezavisimosti Ave., 220072, Minsk, Belarus.
Sergey PetkevichLaboratory of the Chemistry of Heterocyclic Compounds, Institute of Physical Organic Chemistry, National Academy of Sciences of Belarus, 13 Surganov Str., 220072, Minsk, Belarus.
Irina KolesnikLaboratory of the Chemistry of Heterocyclic Compounds, Institute of Physical Organic Chemistry, National Academy of Sciences of Belarus, 13 Surganov Str., 220072, Minsk, Belarus.
Dominik L MichelsComputer, Electrical and Mathematical Science and Engineering Division, King Abdullah University of Science and Technology, Thuwal, 23955-6900, Kingdom of Saudi Arabia.
Dmitry A LyakhovComputer, Electrical and Mathematical Science and Engineering Division, King Abdullah University of Science and Technology, Thuwal, 23955-6900, Kingdom of Saudi Arabia.
Vladimir A KulchitskyBrain Centre, Institute of Physiology, National Academy of Sciences of Belarus, 28 Akademicheskaya Str., 220072, Minsk, Belarus.
National Academy of Sciences of Belarus · BYInstitute of Physiology National Academy of Sciences of Belarus · BYKing Abdullah University of Science and Technology · SAB.I. Stepanov Institute of Physics · BYJiaxing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy is one of the main treatment options for cancer, but it is usually accompanied with negative side effects. The classical drugs combination with synergistic adjuvants can be the solution to this problem, allowing reducing therapeutic dose. Elucidating the mechanism of adjuvant action is of key importance for the selection of the optimal agent. Here we examine the system drug-adjuvant to explain the observed effect in practice. We used the first line drug cisplatin. Morpholinium and 4-methylpiperazinium 4,5-dichloro isothiazol-3-carboxylates were selected as adjuvants. The study of the cisplatin-adjuvant system was carried out by quantum chemical modeling using DFT. It turned out that adjuvants form conjugates with cisplatin that lead to the relocation of frontier molecular orbitals as well as increase of conjugate's dipole moment. It resulted in change of the interaction character with DNA and increase of the bioactivity of the system. The data obtained are the basis for expanding the studies to include other drugs and adjuvants. Oncologists will have opportunity to use "classical" chemotherapy drugs in combination with synergists for those patients who have not been previously recommended to such a treatment because of pronounced toxic side effects.

Indexed as

Drug-Related Side Effects and Adverse ReactionsNeoplasms, NeuroepithelialAdjuvants, ImmunologicAdjuvants, PharmaceuticCisplatinHumansAdjuvants, ImmunologicAdjuvants, PharmaceuticCisplatin

Identifiers

PMID37604841
PMCPMC10442360
OpenAlexW4386033340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.